Weekly Analysts’ Ratings Changes for Guardian Pharmacy Services (GRDN)

A number of firms have modified their ratings and price targets on shares of Guardian Pharmacy Services (NYSE: GRDN) recently:

• 3/12/2026 – Guardian Pharmacy Services had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $40.00 price target on the stock.
• 3/12/2026 – Guardian Pharmacy Services had its price target raised by Truist Financial Corporation from $34.00 to $38.00. They now have a “buy” rating on the stock.
• 3/12/2026 – Guardian Pharmacy Services had its “buy” rating reaffirmed by UBS Group AG.
• 3/12/2026 – Guardian Pharmacy Services had its price target raised by Oppenheimer Holdings, Inc. from $35.00 to $38.00. They now have an “outperform” rating on the stock.

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.